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Abstract
Background: The Rel/NF-κ B transcription factors have been shown to regulate apoptosis in
different cell types, acting as inducers or blockers in a stimuli- and cell type-dependent fashion. One
of the Rel/NF-κ B subunits, RelA, has been shown to be crucial for normal embryonic development,
in which it functions in the embryonic liver as a protector against TNFα -induced physiological
apoptosis. This study assesses whether NF-κ B may be involved in the embryo's response to
teratogens. Fot this, we evaluated how NF-KappaB DNA binding activity in embryonic organs
demonstraiting differential sensitivity to a reference teratogen, cyclophosphamide, correlates with
dysmorphic events induced by the teratogen at the cellular level (excessive apoptosis) and at the
organ level (structural anomalies).
Results: The embryonic brain and liver were used as target organs. We observed that the
Cyclophosphamide-induced excessive apoptosis in the brain, followed by the formation of severe
craniofacial structural anomalies, was accompanied by suppression of NF-κ B DNA-binding activity
as well as by a significant and lasting increase in the activity of caspases 3 and 8. However, in the
liver, in which cyclophosphamide induced transient apoptosis was not followed by
dysmorphogenesis, no suppression of NF-κ B DNA-binding activity was registered and the level of
active caspases 3 and 8 was significantly lower than in the brain. It has also been observed that both
the brain and liver became much more sensitive to the CP-induced teratogenic insult if the embryos
were exposed to a combined treatment with the teratogen and sodium salicylate that suppressed
NF-κ B DNA-binding activity in these organs.
Conclusion: The results of this study demonstrate that suppression of NF-κ B DNA-binding
activity in embryos responding to the teratogenic insult may be associated with their decreased
resistance to this insult. They also suggest that teratogens may suppress NF-κ B DNA-binding
activity in the embryonic tissues in an organ type- and dose-dependent fashion.
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Background
Together with its role in normal embryogenesis [1], apop-
tosis plays also a role in the formation of anomalies in-
duced by teratogens [2,3]. Many teratogens have the
potential to initiate excessive apoptosis, which may lead
to structural anomalies in certain but not in other embry-
onic organs, which are able to resist teratogen-initiated
apoptosis and continue normal development.
Apoptosis is a process realized whereby many parallel and
converging signal transduction pathways, some of which
lead to cell death whereas the others act to provide surviv-
al of targeted cells [4]. These transduction cascades com-
prise molecules that act as activators, effectors and
negative regulators of apoptosis. It is conceivable, there-
fore, that molecules regulating the apoptotic process may
be influential in determining the sensitivity or resistance
of embryos to teratogens.
The Rel/NF-κ B family of transcription factors have recent-
ly been demonstrated to play a crucial role in regulating
apoptotic cell death acting as inducers or blockers of ap-
optosis in a stimulus- and cell type-dependent fashion
[5,6]. Rel/NF-κ B proteins control the expression of target
genes by binding to DNA regulatory elements known as
κ B sites [7–9]. In most cell types, NF-κ B exists in an inac-
tive form in the cytoplasm bound to several Iκ B inhibitor
proteins (Iκ Bs) [7–9]. Its activity is regulated primarily by
phosphorylation of Iκ Bs. In response to a variety of inter-
nal and external stimuli, Iκ Bs are phosphorylated by the
Iκ B kinase (IKK) complex, that is followed by their ubiq-
uitination and degradation leading to the release of and
nuclear translocation of the freed NF-κ B [10,11].
The Rel/NF-κ B family of transcription factors are com-
prised of several related proteins (subunits) including c-
rel, RelA, RelB, p50/p105 and p52/p100 [12]. Experi-
ments in knockout mice addressing the functional role of
NF-κ B proteins revealed that RelA-/- embryos died on day
15 of gestation from massive hepatocyte apoptosis [13].
Subsequent studies [14–18] have led to the conclusion
that RelA acts in the embryonic liver as a protector against
TNFα -induced physiological apoptosis. At the same time,
in experiments with cyclophosphamide, the teratogenic
effect of which is preceded by excessive apoptosis [19,20],
we observed [21] that excessive apoptosis registered in the
liver of embryos tested 24 but not 48 hours after CP treat-
ment. Furthermore, these embryos exhibited structural
craniofacial and limb anomalies, but no dysmorphic
events at the organ level were detected in the liver at this
time point.
Teratogen-induced apoptotic stimuli inevitably alter the
balance between inducers and blockers of physiological
apoptosis, and seem to activate caspases, which are the fi-
nal mediators of the cell death program [4,22]. Since NF-
κ B itself and certain proteins in the NF-κ B-activated sign-
aling pathway may serve as substrates for caspases [23], it
is conceivable, that NF-κ B may function differently in ter-
atogen-targeted and normal embryonic organs. Neverthe-
less, the above-mentioned studies in RelA knockout mice
and our teratological studies in mice exposed to CP indi-
cate that NF-κ B (at least, its RelA subunit) may be in-
volved in regulating not only the physiological but also
teratogen-induced apoptosis in some embryonic organs.
Hence, NF-κ B, while regulating teratogen-induced apop-
tosis, may also regulate the sensitivity/resistance of the
embryo to the teratogenic stress. Therefore, this study was
designed to evaluate whether a correlation exists between
NF-κ B DNA-binding activity in embryonic organs target-
ed by the teratogenic stress and the ability of these organs
to resist a teratogen-induced process of maldevelopment.
As a basic model, we used mouse embryos exposed in vivo
to a reference teratogen, cyclophosphamide (CP) [24–27].
To characterize the process of maldevelopment, fetuses
were examined for external structural anomalies and such
indices as NF-κ B DNA-binding activity, the activity of cas-
pase 8 and 3, apoptosis and histopathological changes.
These changes were evaluated at different time points in
two target organs: the liver, which resists CP-induced ter-
atogenic insult, and the brain, which is very sensitive to
the teratogen [21].
An additional set of experiments was performed with em-
bryos of mice exposed to the teratogen in combination
with sodium salicylate (NaSAL) that has been shown to be
a potent inhibitor of NF-κ B [28–30]. The suppressive ef-
fect of salicylates on NF-κ B DNA-binding activity is pri-
marily associated with their inhibitory effect on Iκ B
kinase-beta (IKKβ ), which is essential in the initiation of
dissociation of NF-κ B from its inhibitor Iκ B and subse-
quent translocation of NF-κ B to the nucleus [30].
Materials and methods
Animal Models
Six to eight weeks old ICR mice were obtained from the
Tel Aviv University animal facility. The animals were
maintained on a 14 hr light/10 hr dark cycle with food
and tap water ad libitum. Females were caged with males
for 3 hr, from 7 to 10 a.m. (dark period) and the presence
of a vaginal plug (11 a.m.) was designated as day 1 of
pregnancy.
To induce a teratogenic effect, cyclophosphamide (CP)
(Sigma, USA) was injected intraperitoneally at 10 a.m. of
day 12 of pregnancy at 15 mg/kg or 40 mg/kg (in 0.5 ml
saline per 20 g body weight).BMC Developmental Biology 2002, 2 http://www.biomedcentral.com/1471-213X/2/2
Page 3 of 11
(page number not for citation purposes)
Sodium salicylate (NaSAL) (Sigma, USA) was injected in-
traperitoneally in a dose of 400 mg/kg body weight at 6,
24 and 30 hours after CP treatment. The first injection of
NaSAL was timed to match the time of the occurrence of
excessive apoptosis in the liver of embryos treated with 40
mg/kg CP (our unpublished data), whereas the second
and third injections (24 and 30 hours after CP injection)
were timed to coincide with the time in which the liver be-
gins to cease the CP-induced apoptosis [21]. The time of
NaSAL injection to intact females matched the time of Na-
SAL injection to CP-treated females.
Pregnant females injected with saline (0.5 ml per 20 g
body weight) were used as a control throughout the study.
Teratological testing
To evaluate the intensity of the CP-induced teratogenic ef-
fect, ten to twelve animals of each group, whether treated
with 15 or 40 mg/kg CP, NaSAL, or CP+NaSAL, were sac-
rificed on day 17 of pregnancy. The uteri were removed,
the number of implantation sites, resorptions and live
embryos was recorded and live fetuses were examined for
external anomalies.
Seven-µm paraffin-embedded sections of formalin-fixed
embryonic tissues were obtained from 3–4 embryos of
different experimental and control groups on day 14 of
pregnancy (48 hours after CP treatment). The sections
were stained with hematoxylin and eosin and used to
characterize dysmorphic events in the liver.
The TUNEL method
Apoptosis was analyzed by Terminal deoxynucleotidyl
transferase (TdT)-mediated dUTP-biotin nick end labeling
(TUNEL) in embryos from the various experimental
groups, collected 48 hours after CP injection and in age-
matched control embryos. Three or four embryos from
the control and experimental groups were fixed in formal-
dehyde, dehydrated in alcohol and xylene and embedded
in paraffin. Tissue sections (7-µm) were prepared and the
localization of apoptotic cells in the tested organs was vis-
ualized by TUNEL as described elsewhere [21].
Evaluation of caspases 3 and 8 activity
Embryonic brains or livers collected from 1–2 litters were
pooled and used to prepare a sample for measurement of
caspase activity. The caspase activity was tested in embryos
c ol l e c t e d a t  6 ,  2 4 o r  48  h o ur s  a f t e r  C P i n j e c t i o n ,  a ge -
matched control embryos and embryos exposed to NaSAL
alone or NaSAL in combination with CP.
The level of active caspase 8 was measured by a Caspase-8
Fluorometric Assay kit (R&D systems Inc., MN, USA) ac-
cording to the manufacturer's instructions. Briefly, brain
or liver samples were homogenized, centrifuged and re-
suspended in 1 ml of PBS. Viable cells were counted and
3 ×  106 cells were resuspended in 60 µl of cold Cell Lysis
Buffer and incubated on ice for 10 minutes.
Caspase-3 activity was evaluated by a FluorAceTM ap-
opain assay kit (Bio-Rad Laboratories, CA, USA) accord-
ing to the manufacturer's instructions. Briefly, cells from
the tested organs were obtained as for caspase-8 activity
test. Then, 6 ×  106 cells were centrifuged, resuspended in
100 µl of apopain lysis buffer and vortexed gently. The
suspensions were frozen and thawed 4–5 times in liquid
nitrogen and a 37° C bath, respectively.
Protein concentration was measured using a DC Protein
Assay kit (BioRad Laboratories, CA, USA) and a 550 Mi-
croplate Reader (Bio-Rad Laboratories, CA, USA) accord-
ing to the manufacturer's instructions. Samples were
frozen in aliquots in liquid nitrogen and stored at -70°C
until use.
The measurements of both caspases were performed using
a Fluorescence Plate Reader FL-600 (Bio-Tex Instruments,
Inc., USA) according to the manufacturer's instructions.
Electrophoretic Mobility Shift Assay (EMSA)
Embryonic brains or livers were collected from 2–3 litters,
pooled and used to prepare a sample of nuclear extract.
Tissue samples were homogenized mechanically in PBS
into single cell suspensions, centrifuged and resuspended
in 1 ml PBS. Viable cells were counted and 15 ×  106 cells
were taken, frozen in liquid nitrogen and stored at -70°C
until use. Nuclear extracts were prepared as described by
Schreiber et al. [31]. Protein concentration was measured
using a DC Protein Assay kit (BioRad Laboratories, CA,
USA) and a 550 Microplate Reader (Bio-Rad Laboratories,
CA, USA) according to the manufacturer's instructions.
Samples were frozen in aliquots in liquid nitrogen and
stored at -70°C until use.
A double stranded oligonucleotide, containing the NF-κ B
site was labeled by [32P] with the Klenow fragment of
DNA polymerase 1 (MBI fermentas, Lithuania) and use as
a probe. The oligonucleotide's sequence is: 5'GATCCA-
GAGGGGACTTTTCCGAGAG 3'; 5'GATCCTCTCG-
GAAAGTCCCCTCTG 3'. (synthesized in the
Oligonucleotide and Peptide Synthesis Laboratory in the
Weizmann Institute of Science, Rehovot, Israel).
Five µg of nuclear extract were preincubated for 15 min-
utes at room temperature in 2 µl Gel Shift Binding Buffer
(20 mM TrisHCl, pH 7.6; 50 mM KCl; 1 mM MgCl2; 0.2
mM EDTA; 0.01% Triton X-100; 5% Glycerol and 0.5 mM
Spermidine in distilled water) ×  10, 1 µg poly dI-dC and
double distilled water (DDW) in a total volume of 19 µl.
One µl of radiolabeled oligonucleotide (20,000 cpm) wasBMC Developmental Biology 2002, 2 http://www.biomedcentral.com/1471-213X/2/2
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added per reaction and samples were incubated for an ad-
ditional 15 minutes at room temperature. Samples were
electrophoresed through a 5.5% acrylamide gel using Tris-
Glycine buffer (40 mM TrisHCl and 195 mM Glycine).
The NF-κ B complexes were identified following autoradi-
ography.
For NF-κ B binding specificity, labeled and unlabeled oli-
gonucleotides (100-fold excess of unlabeled NF-κ B oligo-
nucleotide or 100-fold excess of unlabeled octamer
binding protein (OCT) oligonucleotide) were added after
the binding reaction and incubated for 15 minutes at
room temperature. The OCT binding sequence probe
is:5'TTCAGGGTATGCAAATTATTAGCT3'; 5'TAG-
GAGCTAATAATTTGCATACCCTGAAGATC 3' (synthe-
sized in the Oligonucleotide and Peptide Synthesis
Laboratory in the Weizmann Institute of Science, Re-
hovot, Israel).
For the supershift assay, 6 µg of specific anti p50 or p65
(RelA) antibodies (#SC-114X and #SC-372X [18], respec-
tively, Santa Cruz Biotechnologies, Inc., CA, USA) were
added to the binding reaction and incubated for 15 min-
utes before adding the DNA probe.
Results of EMSA were reproduced in 3 successive experi-
ments using different samples of liver or brain collected
from embryos of the control and experimental groups.
Statistical analysis
Caspase activity
Six to eight samples obtained from the brain or liver of
embryos of control and experimental groups were tested
for caspase 3 and caspase 8 activity. Fmax-test for homoge-
neity of variances and ANOVA were used to test whether
the data characterizing the activity of a tested caspase in a
given organ of control embryos at a given time point
matching the time after CP injection (6, 24 and 48 hours)
may be pooled and treated as a unified control group [32].
Since this analysis did not reveal statistically significant
differences, the results obtained in different control
groups were pooled and the average values representing
the activity of caspase-3 and caspase-8 in the brain and liv-
er of control embryos were calculated. Caspase activity in
an experimental sample was expressed as the ratio of the
value registered in a tested sample by the fluorometric
reading to the average value representing the activity of a
given caspase in a given embryonic organ of control em-
bryos. The GT2-method for multiple comparisons [32]
was used for statistical analysis of the data obtained. The
two-tailed level of significance of differences was = 0.05.
Teratological testing
Statistical analysis of the teratological data was performed
on a litter basis. The proportions of malformed fetuses
and resorptions per litter were transformed to arcsine val-
ues by Freeman-Turkey's binomial method as described
elsewhere [33] and GT2-method for multiple compari-
sons was used for statistical analysis of the data obtained.
The two-tailed level of significance of differences was =
0.05.
Results
Effects induced by CP
External structural anomalies
CP exerted a very strong teratogenic effect at a dose of 40
mg/kg: all fetuses were severely malformed and growth re-
tarded (Table 1 and Fig. 1). The spectrum of anomalies in-
cluded mainly craniofacial anomalies such as severe
microcephaly, agnathia, open eyes, limb reduction anom-
alies such as phocomelia or amelia, as well as a trunk
anomaly, eventration of the abdominal wall, and absence
of the tail (Table 1 and Fig. 1). This dose of CP also result-
ed in a high resorption rate (approximately, 80%).
Figure 1
External structural anomalies in 17-day fetuses treated with
CP alone or in combination with NaSAL. Top row: Left – a
control fetus. Right – a fetus treated with NaSAL. No exter-
nal anomalies were observed in these embryos. Bottom
row: Left – a fetus treated with 40 mg/kg CP exhibits severe
growth retardation, eventration of the abdominal wall, phoc-
omelia and amelia (hindlimbs), absence of tail, agnathia, open
eyes, severe microcephaly. Center: a fetus treated with 15
mg/kg CP exhibits light growth retardation, bowed tail, syn-
dactyly and ectrodactyly. Right: a fetus treated with 15 mg/
kg CP and NaSAL exhibits more severe growth retardation
than the embryo treated with this dose of CP alone and such
anomalies as microcephaly, open eyes, micrognathia, adactyly
(forelimbs) and meromelia (hindlimbs), short tail, eventration
of the abdominal wall.BMC Developmental Biology 2002, 2 http://www.biomedcentral.com/1471-213X/2/2
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The teratogenic effect CP at 15 mg/kg was significantly less
prominent: approximately, 30% of fetuses had no exter-
nal anomalies, whereas 70% exhibited external tail and
digit anomalies such as short or crooked tail, syndactyly
and ectrodactyly (Table 1 and Fig. 1). Only single fetuses
exhibited more severe anomalies such as open eyes, mer-
omelia and eventration of the abdominal wall. The level
of resorptions in females treated with this dose of CP did
not differ much from that in controls (Table 1).
Apoptosis
CP-induced apoptosis was evaluated in two target organs,
the embryonic brain and liver. Our previous studies ad-
dressing the role of apoptosis in CP teratogenicity re-
vealed that the temporal pattern of apoptosis induced by
CP in these organs is dose- and organ type-dependent.
Thus, apoptosis induced CP at 40 mg/kg was registered in
the brain and liver of 13 day embryos (E13) by the TUNEL
assay and FACS analysis [20,21]. However, if CP was in-
jected at a dose of 15 mg/kg, no apoptosis was registered
in the liver of E13 [20]. Apoptosis was also observed in the
brain of 14 day embryos (E14) treated with 40 mg/kg CP
[21].
In agreement with the above observations, in this study
we also observed massive apoptosis in the brain of E14 ex-
posed to 40 mg/kg CP (Fig. 2B). However, no excessive
apoptosis was observed in the liver of these embryos (Fig.
3B).
The experiments on temporal pattern of expression of ac-
tive caspase 3 and caspase 8 in the brain and liver revealed
Table 1: Effect of cyclophosphamide (CP) and sodium salicylate (NaSAL) on embryonic development
INDICES Groups (treatment/ CP dose)
CP 40 mg/kg CP 15 mg/kg NaSAL NaSAL+ CP 15 
mg/kg
Control
Litters examined 10 11 12 10 10
Implantation sites/litter 11.3 10.9 11.5 11.6 10.8
Live fetuses/litter 2.5 9.7 10.3 9.8 9.8
Resorptions %
arcsine (M ± SE)
77.9*
60.5 ± 3.1a
10.8
21.8 ± 2.6b
10.9
21.8 ± 3.2b
15.5
25.2 ± 3.4b
9.2
20.6 ± 2.8 b
Fetal weight
(M ± SE)
0.26 ±
0.02a
0.60 ±
0.04 b
0.74 ±
0.03 c
0.44 ±
0.03d
0.75 ±
0.02c
Fetuses with external structural anomalies
Total examined
malformed (%)
arcsine (M ± SE)
25
25(100)
76.9 ± 1.6a
107
76(71.0)
56.3 ± 4.1 b
123
0
8.7 ± 0.3 c
98
98 (100)
81.1 ± 1.3a
98
0
8.9 ± 0.4c
Types of anomalies
Craniofacial
anomalies (%)
arcsine (M ± SE)
25(100)
76.9 ± 1.6a
5 (4.7)
13.7 ± 4.2b
0
8.7 ± 0.3 b
65 (66.3)
53.7 ± 4.9c
0
8.9 ± 0.4 b
Limb reduction
anomalies (%)
arcsine (M ± SE)
25(100)
76.9 ± 1.6a
5 (4.7)
13.7 ± 4.2b
0
8.7 ± 0.3 b
70(71.4)
56.5 ± 5.1c
0
8.9 ± 0.4 b
Digit anomalies
(%)
arcsine (M ± SE)
0
13.1 ± 0.6a
71 (66.3)
53.7 ± 3.6b
0
8.7 ± 0.3a
28 (28.6)
33.5 ± 4.5c
0
8.9 ± 0.4a
Tail anomalies
(%)
arcsine (M ± SE)
25(100)
76.9 ± 1.6a
76(71.0)
60.6 ± 3.1b
0
8.7 ± 0.3 c
98 (100)
81.1 ± 1.3a
0
8.9 ± 0.4c
Trunk anomalies
(%)
arcsine (M ± SE)
25(100)
76.9 ± 1.6a
3 (2.8)
12.4 ± 2.0 b
0
8.7 ± 0.3 b
36 (36.7)
38.0 ± 3.6C
0
8.9 ± 0.4 b
The percentage of resorptions and malformed fetuses presented in Table 1 was calculated using the implantation site and the fetus, respectively, as 
independent variables. Arcsine values were calculated on a litter basis and analyzed statistically by GT-2 method. Means not sharing common super-
scripts are significantly different. The description of craniofacial, limb reduction, digit, tail and trunk anomalies registered in fetuses of a given group 
is presented in the text. *- In 4 litters the resorption rate reached 100%.BMC Developmental Biology 2002, 2 http://www.biomedcentral.com/1471-213X/2/2
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that the extent in which 40 mg/kg CP activated caspase 3
and caspase 8 is different in these organs. A 22-fold in-
crease in caspase 8 activity was observed in the brain 24
hours after exposure to 40 mg/kg CP, whereas in the liver
the level of active caspases 8 was significantly lower (Fig.
4A and 4B). We also observed that the extent of CP-in-
duced caspase 3 activation was lesser than that of caspases
8 (Fig. 4C and 4D). Still, caspase 3 activation was more
prominent in the brain than in the liver. It is important to
emphasize that 48 hours after the teratogenic insult, the
level of both active caspases in the brain remained to be
significantly higher than that in controls, whereas in the
liver it was identical to that in controls (Fig. 4).
The low dose of CP increased only the level of active cas-
pase 8 but not caspase 3 in both tested organs (Fig 4). Fur-
thermore, the increased level of active caspase 8 was
observed in the brain of embryos tested 24 but not 48
hours after CP injection (Fig. 4A).
NF-κ B DNA-binding activity in the brain and liver of CP-treated em-
bryos
EMSA of nuclear extracts from of control E13 and E14 re-
vealed the existence of active NF-κ B complexes in both the
brain and liver (Fig. 5A, lanes 1,3,5 and 7). Specificity of
NF-κ B binding in these and other nuclear extracts present-
ed in Fig. 5A was proven by EMSA of the same nuclear ex-
tracts with 100-fold excess of unlabeled NF-κ B
oligonucleotide or 100-fold excess of OCT oligonucle-
otide. (Fig. 5B).
Supershift analysis was performed with nuclear extracts
from the brain of E13 and E14 as well as from the liver of
E13 and E14. Since only p65/p50 heterodimers and p50
homodimers were found to be the active forms of NF-κ B
in the embryo between days 12 and 14 of pregnancy [18],
only anti p65 and anti p50 antibodies were used in the
present study. It has been revealed that antibody against
p65 inhibited the formation of the top band but not the
bottom one, whereas antibody against p50 inhibited for-
mation of both top and bottom bands (Fig. 5B). These re-
sults concur with those cited above [18] and suggest that
active NF-κ B complexes in the embryonic brain and liver
primarily composed of p65/p50 heterodimers and p50/
p50 homodimers.
Although the pattern of the constitutive expression of ac-
tive NF-κ B complexes in the embryonic liver and brain
was identical, NF-κ B DNA-binding activity was different
in the organs of embryos exposed to the teratogen. In-
deed, CP treatment in a dose of 40 mg/kg resulted in the
suppression of NF-κ B DNA-binding activity in the brain
of E13 (Fig. 5A, lane 2) but not in the liver (Fig. 5A, lane
6). Twenty-four hours later, NF-κ B DNA-binding activity
could be detected in the brain, but it was lower than that
found in the brain of control embryos (Fig. 5A, lanes 4
and 3, respectively). At the same time, in the liver of E14,
Figure 2
Representative TUNEL-stained sections of the brain of E14.
All sections are midsagittal and present a region of the
embryonic telencephalon containing the ependyma layer,
mantle and marginal layers. A – a control embryo; B – an
embryo treated with 40 mg/kg CP; C – an embryo treated
with NaSAL; D – an embryo treated with 15 mg/kg CP
+NaSAL. Scale bar = 10 µm
Figure 3
Representative TUNEL-stained sections of the liver of E14.
All sections are midsagittal. A – a control embryo; B – an
embryo treated with 40 mg/kg CP; C – an embryo treated
with NaSAL; D – an embryo treated with 40 mg/kg CP
+NaSAL. Scale bar = 10 µmBMC Developmental Biology 2002, 2 http://www.biomedcentral.com/1471-213X/2/2
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the expression of active NF-κ B complexes was similar to
controls (Fig. 5A, lanes 8 and 7, respectively).
Thus, the above experiments showed that in the liver,
which demonstrates the ability to cease CP-induced apop-
tosis, the teratogenic insult was not followed by suppres-
sion of NF-κ B DNA-binding activity. At the same, the
suppression of NF-κ B DNA-binding activity was observed
in the brain, in which the CP-induced excessive apoptosis
culminates in structural anomalies.
Effects induced by the combined treatment with CP and 
NaSAL
To investigate whether the combined treatment with Na-
SAL and CP modifies sensitivity of the brain to the tera-
togen, CP was injected in a dose of 15 mg/kg, which
induced craniofacial anomalies in less than 5% of fetuses.
We found that a combined treatment significantly in-
creased the sensitivity of embryos to CP. Indeed, in litters
of females exposed to CP and NaSAL approximately, 70%
of fetuses were severely growth retarded and exhibited
brain, craniofacial and limb reduction anomalies such as
microcephaly, open eyes, micrognathia, adactyly of the
forelimbs and meromelia of hindlimbs, eventration of the
abdominal wall (Table 1 and Fig. 1). Fetuses of females
exposed to NaSAL alone did not demonstrate external
anomalies (Table 1 and Fig. 1).
Combined treatment with this dose of CP and NaSAL was
followed by massive apoptosis in the embryonic brain
(Fig. 2D), the intensity of which was comparable with that
registered in the brain of embryos treated with 40 mg/kg
CP (Fig. 2B). No excessive apoptosis was observed in the
brain of E14 exposed to NaSAL alone (Fig. 2C) or to 15
mg/kg CP alone (data not shown).
Finally, the level of active NF-κ B complexes in nuclear ex-
tracts isolated from the brain of embryos exposed to the
combined treatment with CP and NaSAL (Fig 6B, lane 2)
was lower that that of controls (Fig 6B, lane 3) and similar
to that in nuclear extracts from the brain of embryos treat-
Figure 4
Active caspase 8 and caspase 3 expression in the embryonic
brain and liver of control embryos and embryos exposed to
CP. Results obtained in experimental groups are presented
as 95% limits for the means (fold increase) calculated by
GT2-method. Means with limits that do not overlap are sig-
nificantly different. Means with lower limits < 1 (the level of
the activity of the caspases in controls) do not differ signifi-
cantly from controls.
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Figure 5
NF-κ B complex formation in the embryonic brain and
liver.A: Nuclear extracts from the brain (lanes 1–4) and liver
(lanes 5–8) of E13 and E 14, control and exposed to 40 mg/kg
CP. 1 – E13, control; 2 – E13, CP; 3 – E14, control; 4 – E14,
CP; 5 – E13, control; 6 – E13, CP; 7 – E14, control; 8 – E14,
CP; 9 – no sample.B: Supershift analysis of -κ B-binding pro-
teins presented in nuclear extract from the brain of E13
demonstrating p65/p50 heterodimers (top band) and p50/
p50 homodimers (bottom band). Specificity of binding was
determined by competition with 100-fold excess of unlabeled
NF-κ B oligonucleotide or 100-fold excess of OCT oligonu-
cleotide.BMC Developmental Biology 2002, 2 http://www.biomedcentral.com/1471-213X/2/2
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ed with 40 mg/kg CP (Fig 6B, lane 4). CP alone did not al-
ter the amount of NF-κ B binding as compared to controls
(Fig. 6B, lanes 1 and 3).
While evaluating whether the combined treatment with
NaSAL and CP modifies the sensitivity of the liver to the
teratogen, we injected CP in a dose of 40 mg/kg. Our pre-
vious studies [21] have shown that 14 day embryos of fe-
males exposed to this dose of CP were severely growth
retarded but the size of their liver did not visually differ
from that of age-matching control embryos.
In this study we observed that the size of the liver of E14
exposed to 40 mg/kg CP and NaSAL was obviously small-
er than that of embryos exposed to the teratogen alone.
The histological examination revealed no histopathologi-
cal changes in the liver of embryos treated with 40 mg/kg
CP but in the liver of embryos exposed to the combined
treatment with CP and NaSAL extensive areas of swelling
as well as the existence of cells without clear cell borders
were observed (data not shown). TUNEL analysis revealed
no excessive apoptosis in the liver of E14 exposed to Na-
SAL alone (Fig 3C). At the same time, some liver areas of
embryos exposed to CP and NaSAL demonstrated an in-
creased number of TUNEL-positive nuclei (Fig. 3D).
We also observed that combined treatment resulted in the
suppression of NF-κ B DNA-binding activity in the liver
(Fig. 6A, line 3). It is interesting that NF-κ B DNA-binding
activity was not altered in the liver of embryos exposed to
NaSAL alone (Fig. 6A, lane 5) and the liver of these embry-
os neither visually nor histologically differed from the liv-
er of controls (data not presented).
Thus, these experiments have showed that the combined
treatment with CP and NaSAL increases the sensitivity of
both tested organs to the teratogen and this increase is ac-
companied by suppression of NF-κ B DNA-binding activi-
ty in these embryonic organs.
Discussion
NF-κ B has been detected in practically all murine embry-
onic tissues, from approximately day 12 of pregnancy on-
wards [34]. Gene targeting experiments suggest that one
of the Rel/NF-κ B subunits, RelA, functions as a negative
regulator of TNFα -induced physiological apoptosis in
hepatocytes of E13 – E15 [35]. These findings gave an im-
petus to investigate NF-κ B DNA-binding activity in em-
bryos responding to the teratogenic insult, which is
followed by excessive apoptosis.
The main observations in this study may be summarized
as follows.
In the brain, teratogen-induced excessive apoptosis that
culminated in fetal anencephaly was accompanied by the
suppression of NF-κ B DNA-binding activity. However, in
the liver, demonstrating the ability to stop apoptosis fol-
lowing this teratogenic insult without signs of dysmor-
phogenesis, suppression of NF-κ B DNA-binding activity
was not observed.
In the light of evidence demonstrating that RelA-/- embry-
os die from massive hepatocyte apoptosis induced by
TNFα  [14–18], the above observations seem to be expect-
able and may serve as a basis to suggest that NF-κ B might
be among mechanisms negatively regulating CP-induced
apoptosis in the tested organs and, hence, protecting the
embryo from the teratogen.
The results of experiments in mice treated with the tera-
togen in combination with NaSAL support the concept.
Indeed, suppression of NF-kB DNA-binding activity in the
liver was associated with a prominent decrease in liver size
and histopathological changes in this organ or, in other
words, with dysmorphic events suggesting an increase in
the sensitivity of the liver to CP-induced teratogenic in-
sult.
Surprisingly, we observed that these dysmorphic events
were accompanied by an increased number of TUNEL-
positive nuclei only in some liver areas. Since no excessive
apoptosis was found at this time point in the liver of em-
bryos exposed to the teratogen alone, this finding does
suggest that the ability of the liver to resist CP-induced ap-
optosis was impaired in embryos exposed to CP and Na-
Figure 6
NF-κ B complex formation in the liver and brain of E14
embryos exposed CP in combination with NaSAL.A: Nuclear
extracts from the liver: 1 – no sample; 2 – E14, control; 3 –
E14, 40 mg/kg CP+NaSAL; 4 – E14, 40 mg/kg CP; 5 – E14,
NaSAL.B: Nuclear extracts from the brain: 1 – E14, 15 mg/kg
CP; 2 – E14, 15 mg/kg CP + NaSAL; 3 – E14, control; 4 –
E14, 40 mg/kg CP; 5 – no sampleBMC Developmental Biology 2002, 2 http://www.biomedcentral.com/1471-213X/2/2
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SAL. Anyway, the intensity of apoptosis registered in the
liver of these embryos was significantly lower than that in
RelA-knockout embryos demonstrating massive liver ap-
optosis [13,16,18].
The reasons for this discrepancy remain unclear. The re-
sults of recent studies suggest that NF-κ B may be essential
for liver regeneration in adult mice [36,37], whereas in the
embryonic liver RelA serves a vital protective function
against TNFα  apoptotic signaling but it is not critical for
liver development [18]. These findings suggest that in em-
bryonic liver cells surviving a CP-induced cytotoxic insult,
NF-κ B begins to act not only as a negative regulator of ap-
optosis but also as an inducer of cell proliferation, thus
possibly explaining differences in the patterns of liver de-
generation demonstrated by RelA-knockout embryos and
those exposed to the teratogen in combination with Na-
SAL, and additional studies are planned to test this possi-
bility.
The other explanation may be due to salicylates not only
exert inhibitory effects on NF-κ B activity but also of alter
the expression of a number of other molecules, e.g. those
operating in mitogen-activated protein (MAP) kinase sig-
naling pathways [38–40]. Three MAP kinases, the extracel-
lular signal-regulated kinase (ERK), the c-Jun N-terminal
kinase (JNK), the stress-activated protein kinase, p38 as
well as different components of these three signaling
pathways are expressed during mouse embryogenesis
[41–43]. Hence, some molecules of MAP kinase signaling
pathways may, along with NF-κ B, be involved in mediat-
ing dysmorphic events induced by the teratogen in com-
bination with NaSAL.
Combined treatment with NaSAL and the low dose of CP
that resulted in the suppression of NF-κ B DNA-binding
activity in the brain was also followed by the occurrence
of craniofacial structural anomalies, which lacked in em-
bryos exposed to CP alone. Moreover, these embryos also
demonstrated an increase in severity of limb reduction
anomalies (adactyly and meromelia vs. digit anomalies).
Since NF-κ B is ubiquitously expressed in embryonic tis-
sues at this stage of development and the embryonic
limbs are, at least, as sensitive as the brain to the teratogen
[21], these observations may support the argument for the
role of NF-κ B in mediating the teratogenic response to CP.
In this context, it is interesting to note studies demonstrat-
ing that acrolein, one of the teratogenic metabolites of CP
[24] induces a dose-dependent inhibition of NF-κ B activa-
tion in human lung adenocarcinoma (A549) cells [44]
and human alveolar macrophages [45].
It is also worth mentioning that NaSAL suppressed NF-κ B
DNA-binding activity only in the liver and brain of embry-
os pretreated with CP. This finding raises the question on
whether mechanisms regulating the constitutive NF-kB
DNA-binding activity differ from those regulating NF-kB
DNA-binding activity in cells responding to the cytotoxic
insult.
Finally, some results of this study seem to provide some
hints into mechanisms through which NF-κ B might be in-
volved in regulating the teratogenic response.
Indeed, one of these mechanisms whereby NF-κ B serves
the antiapoptotic function is presently associated with the
interaction between NF-κ B and molecules, which act as
positive regulators of apoptosis [5]. Caspase 3 and caspase
8 are such molecules and it has been reported that nega-
tive feedback mechanisms regulating caspase activation
and NF-κ B activation exist [5,6,46]. These caspases are in-
volved in transducing and executing both cellular stress-
and death receptor-initiated apoptotic stimuli [4,22].
DNA-damaging agents, such as CP, are cellular stress in-
ducers [22] and have also the potential to induce apopto-
sis via death receptor-mediated signal transduction
pathways [47]. Caspase 3 has recently been reported to be
involved in CP-induced apoptosis in an organ type-de-
pendent manner [27]. Results of our study confirm the
above observation and suggest that caspase 8 may also be
involved in mediating CP-induced apoptosis.
The possibility, that "caspase – NF-κ B interaction" might
be one of the mechanisms predetermining the response of
the embryo to CP-induced teratogenic insult is suggested
by the comparative analysis of the activation patterns of
both these caspases and NF-κ B DNA-binding activity in
the brain and liver. Thus, one can see, that 6 hours after
CP treatment the levels of active caspase 8 as well as cas-
pase 3 were almost equal in the brain and liver. However,
24 hours after CP treatment, the level of both caspases was
significantly increased in the brain but it remained the
same in the liver. No active NF-κ B complexes were ob-
served in the brain at this time point, whereas in the liver
the level of the active NF-κ B expression did not differ from
that in controls.
These findings suggest that "caspase – NF-κ B interaction"
might occur in the tested organs at the time interval be-
tween 6 and 24 hours after CP treatment and result in the
suppression of NF-κ B DNA-binding activity in the brain
but prevention of excessive activation of caspases in the
liver. This may explain the resistance of the liver and the
sensitivity of the brain to the teratogen and, hence, allows
hypothesizing on the involvement of NF-κ B in the tera-
togenic response through "NF-κ B – caspases" negative
feedback mechanisms acting in an organ type-dependent
fashion.BMC Developmental Biology 2002, 2 http://www.biomedcentral.com/1471-213X/2/2
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Conclusions
The results of this study demonstrate that teratogenic sus-
ceptibility of embryonic tissues to CP correlates inversely
with local NF-κ B DNA-binding activity prior to target or-
gan dysmorphogenesis. They also suggest that teratogens
may suppress NF-κ B DNA-binding activity in the embry-
onic tissues in an organ type- and dose-dependent fash-
ion. Together, the phenomena described in this work may
serve as a basis for further studies investigating the role of
NF-κ B in teratogenesis.
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